Vivo Bio Tech's Q1 FY 2026-27 Quarterly Results
- 14 Jul 2026
Result Summary
- Vivo Bio Tech Ltd reported a 0.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 13.4%.
- Its expenses for the quarter were up by 4.6% QoQ and 25.4% YoY.
- The net profit decreased 103.7% QoQ and decreased 85.8% YoY.
- The earnings per share (EPS) of Vivo Bio Tech Ltd stood at 0.08 during Q1 FY 2026-27.
Financial Statments for Q1 FY 2026-27
(₹ crores) | Q1FY27 | Q4FY26 | Q1FY26 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 14.34 | 14.23 | 12.65 | 0.8% | 13.4% |
Total Expenses | 14.00 | 13.38 | 11.16 | 4.6% | 25.4% |
Profit Before Tax | 0.34 | 0.25 | 1.48 | 36.0% | -77.0% |
Tax | 0.15 | 5.41 | 0.14 | -97.2% | 7.1% |
Profit After Tax | 0.19 | -5.16 | 1.34 | -103.7% | -85.8% |
Earnings Per Share | 0.08 | -2.52 | 0.74 | -103.2% | -89.2% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Vivo Bio Tech Ltd is a company operating within the biotechnology sector, primarily engaged in research and development services, manufacturing, and offering solutions pertinent to the life sciences industry. The company is known for its focus on innovation and technological advancement in biotechnology, which encompasses a range of products and services related to pharmaceutical development, clinical research, and biopharmaceutical production. Any recent major developments specific to Vivo Bio Tech Ltd are not available within the scope of the provided data.
Revenue
In Q1FY27, Vivo Bio Tech Ltd reported a total income of ₹14.34 crores, which represents a 0.8% increase from the previous quarter (Q4FY26) where the total income was ₹14.23 crores. When compared to the same quarter last year (Q1FY26), the total income grew by 13.4% from ₹12.65 crores. This year-over-year increase suggests a growth trajectory in the company's revenue, reflecting potential expansion in its business operations or an increase in demand for its services.
Profitability
The profitability of Vivo Bio Tech Ltd during Q1FY27 showed mixed results. Profit Before Tax (PBT) stood at ₹0.34 crores, marking a 36.0% increase from the previous quarter's PBT of ₹0.25 crores. However, when compared year-over-year, there was a significant decline of 77.0% from ₹1.48 crores in Q1FY26. The Profit After Tax (PAT) showed a positive value of ₹0.19 crores in Q1FY27, a recovery from a negative PAT of -₹5.16 crores in Q4FY26. Compared to a PAT of ₹1.34 crores in Q1FY26, the current quarter reflects an 85.8% decrease. This resulted in an Earnings Per Share (EPS) of ₹0.08 in Q1FY27, compared to an EPS of ₹0.74 in Q1FY26, indicating an 89.2% decline year-over-year.
Operating Metrics
The operating metrics for Vivo Bio Tech Ltd highlight changes in expenses and tax obligations impacting overall financial performance. Total expenses increased by 4.6% from Q4FY26 to Q1FY27, rising from ₹13.38 crores to ₹14.00 crores. Year-over-year, the total expenses rose significantly by 25.4% from ₹11.16 crores in Q1FY26. The tax expense in Q1FY27 was ₹0.15 crores, significantly lower than the ₹5.41 crores reported in Q4FY26, reflecting a 97.2% decrease. Compared to Q1FY26, the tax expense increased by 7.1% from ₹0.14 crores. These metrics reflect changes in the cost structure and tax liabilities across different reporting periods.
FAQs
Vivo Bio Tech Ltd announced its Q1 FY 2026-27 results on 14 July, 2026.
Vivo Bio Tech Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of Vivo Bio Tech Ltd Q1 FY 2026-27 results include:
- Revenue: ₹14.34 crore
- Net Profit: ₹0.19 crore
- EBITDA: ₹5.11 crore
- Year-over-Year Growth: 13.4%
- Quarter-over-Quarter Growth: 0.8%
Vivo Bio Tech Ltd reported a net loss of ₹0.19 crore in Q1 FY 2026-27, reflecting a -85.8% year-over-year growth.
Vivo Bio Tech Ltd posted a revenue of ₹14.34 crore in Q1 FY 2026-27.